Detalles de la búsqueda
1.
Safety and immunogenicity of the H56:IC31 tuberculosis vaccine candidate in adults successfully treated for drug-susceptible pulmonary TB: a phase 1 randomized trial.
J Infect Dis
; 2024 Apr 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-38557639
2.
Prevention of M. tuberculosis Infection with H4:IC31 Vaccine or BCG Revaccination.
N Engl J Med
; 379(2): 138-149, 2018 07 12.
Artículo
en Inglés
| MEDLINE | ID: mdl-29996082
3.
Dose Optimization of H56:IC31 Vaccine for Tuberculosis-Endemic Populations. A Double-Blind, Placebo-controlled, Dose-Selection Trial.
Am J Respir Crit Care Med
; 199(2): 220-231, 2019 01 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-30092143
4.
Adjuvanted HLA-supertype restricted subdominant peptides induce new T-cell immunity during untreated HIV-1-infection.
Clin Immunol
; 146(2): 120-30, 2013 Feb.
Artículo
en Inglés
| MEDLINE | ID: mdl-23314272
5.
Availability and use of Standards in vaccine development.
NPJ Vaccines
; 8(1): 95, 2023 Jun 30.
Artículo
en Inglés
| MEDLINE | ID: mdl-37391580
6.
First in humans: a new molecularly defined vaccine shows excellent safety and strong induction of long-lived Mycobacterium tuberculosis-specific Th1-cell like responses.
Hum Vaccin
; 6(12): 1007-15, 2010 Dec.
Artículo
en Inglés
| MEDLINE | ID: mdl-21178394
7.
A phase 1b randomized study of the safety and immunological responses to vaccination with H4:IC31, H56:IC31, and BCG revaccination in Mycobacterium tuberculosis-uninfected adolescents in Cape Town, South Africa.
EClinicalMedicine
; 21: 100313, 2020 Apr.
Artículo
en Inglés
| MEDLINE | ID: mdl-32382714
8.
Safety and immunogenicity of the chlamydia vaccine candidate CTH522 adjuvanted with CAF01 liposomes or aluminium hydroxide: a first-in-human, randomised, double-blind, placebo-controlled, phase 1 trial.
Lancet Infect Dis
; 19(10): 1091-1100, 2019 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-31416692
9.
A phase I, open-label trial on the safety and immunogenicity of the adjuvanted tuberculosis subunit vaccine H1/IC31® in people living in a TB-endemic area.
Trials
; 19(1): 24, 2018 Jan 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-29321075
10.
Immunogenicity and safety of three aluminium hydroxide adjuvanted vaccines with reduced doses of inactivated polio vaccine (IPV-Al) compared with standard IPV in young infants in the Dominican Republic: a phase 2, non-inferiority, observer-blinded, randomised, and controlled dose investigation trial.
Lancet Infect Dis
; 17(7): 745-753, 2017 07.
Artículo
en Inglés
| MEDLINE | ID: mdl-28454674
11.
First-in-human safety and immunogenicity investigations of three adjuvanted reduced dose inactivated poliovirus vaccines (IPV-Al SSI) compared to full dose IPV Vaccine SSI when given as a booster vaccination to adolescents with a history of IPV vaccination at 3, 5, 12months and 5years of age.
Vaccine
; 35(4): 596-604, 2017 01 23.
Artículo
en Inglés
| MEDLINE | ID: mdl-28027810
12.
H1:IC31 vaccination is safe and induces long-lived TNF-α+IL-2+CD4 T cell responses in M. tuberculosis infected and uninfected adolescents: A randomized trial.
Vaccine
; 35(1): 132-141, 2017 01 03.
Artículo
en Inglés
| MEDLINE | ID: mdl-27866772
13.
Safety and immunogenicity of the novel H4:IC31 tuberculosis vaccine candidate in BCG-vaccinated adults: Two phase I dose escalation trials.
Vaccine
; 35(12): 1652-1661, 2017 03 14.
Artículo
en Inglés
| MEDLINE | ID: mdl-28216183
14.
Antigen Availability Shapes T Cell Differentiation and Function during Tuberculosis.
Cell Host Microbe
; 21(6): 695-706.e5, 2017 Jun 14.
Artículo
en Inglés
| MEDLINE | ID: mdl-28618268
15.
Safety and efficacy of the C-Tb skin test to diagnose Mycobacterium tuberculosis infection, compared with an interferon γ release assay and the tuberculin skin test: a phase 3, double-blind, randomised, controlled trial.
Lancet Respir Med
; 5(4): 259-268, 2017 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-28159608
16.
Antiviral Innate Immune Activation in HIV-Infected Adults Negatively Affects H1/IC31-Induced Vaccine-Specific Memory CD4+ T Cells.
Clin Vaccine Immunol
; 22(7): 688-96, 2015 Jul.
Artículo
en Inglés
| MEDLINE | ID: mdl-25924764
17.
The tuberculosis vaccine H4:IC31 is safe and induces a persistent polyfunctional CD4 T cell response in South African adults: A randomized controlled trial.
Vaccine
; 33(30): 3592-9, 2015 Jul 09.
Artículo
en Inglés
| MEDLINE | ID: mdl-26048780
18.
First-in-human trial of the post-exposure tuberculosis vaccine H56:IC31 in Mycobacterium tuberculosis infected and non-infected healthy adults.
Vaccine
; 33(33): 4130-40, 2015 Aug 07.
Artículo
en Inglés
| MEDLINE | ID: mdl-26095509
19.
A novel liposomal adjuvant system, CAF01, promotes long-lived Mycobacterium tuberculosis-specific T-cell responses in human.
Vaccine
; 32(52): 7098-107, 2014 Dec 12.
Artículo
en Inglés
| MEDLINE | ID: mdl-25454872
20.
Safety and immunogenicity of H1/IC31®, an adjuvanted TB subunit vaccine, in HIV-infected adults with CD4+ lymphocyte counts greater than 350 cells/mm3: a phase II, multi-centre, double-blind, randomized, placebo-controlled trial.
PLoS One
; 9(12): e114602, 2014.
Artículo
en Inglés
| MEDLINE | ID: mdl-25490675